T1	PrimaryOutcome 50 78	time to clinical improvement
T2	OutcomeDefinition 86 831	the duration from randomization to the improvement of at least 1 point on a 7-category ordinal scale (adopted from a scale for hospitalized patients with severe influenza)19 or discharge from hospital, whichever occurred first. The 7-category ordinal scale was graded based on the following scheme: 1 for nonhospitalized with normal activities; 2 for nonhospitalized but unable to resume normal activities; 3 for hospitalized but not requiring supplemental oxygen; 4 for hospitalized and requiring supplemental oxygen; 5 for hospitalized and requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6 for hospitalized and requiring extracorporeal membrane oxygenation, invasive ventilation, or both; and 7 for death
T3	SecondaryOutcome 862 884	lymphocyte cell counts
T4	TimeFrame 885 907	on day 5 posttreatment
T5	SecondaryOutcome 909 918	mortality
T6	TimeFrame 919 928	at day 21
T7	SecondaryOutcome 934 992	proportions of patients progressing to critical conditions
T8	OutcomeDefinition 998 1058	acute respiratory distress syndrome, sepsis, or septic shock
T9	SecondaryOutcome 1065 1076	viral loads
T10	OutcomeDefinition 1078 1145	reflected by the Ct values as measured with real-time RT-PCR assays
T11	TimeFrame 1147 1156	at day 21
R1	MeasuredAt Arg1:T3 Arg2:T4	
R2	MeasuredAt Arg1:T5 Arg2:T6	
R3	DefinedAs Arg1:T7 Arg2:T8	
R4	DefinedAs Arg1:T9 Arg2:T10	
R5	MeasuredAt Arg1:T9 Arg2:T11	
T12	OtherOutcome 1183 1197	adverse events
T13	OtherOutcome 1199 1221	serious adverse events
T14	OtherOutcome 1227 1265	premature discontinuation of treatment
T15	OutcomeDefinition 1297 1382	National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
R6	DefinedAs Arg1:T12 Arg2:T15	
